Proton Pump Inhibitors serve as the cornerstone of management of Upper Gastrointestinal bleeding. In Nepal, intravenous Pantoprazole is widely used. One of the rare complications of intravenous Pantoprazole is thrombocytopenia which may lead to paradoxical increase in bleeding possibility.
Introduction
Pantoprazole is a widely used drug, especially in the setting of acute upper GI bleed. These agents are generally well tolerated and the most commonly reported adverse effects include headache and mild gastrointestinal symptoms. 1 Similarly, with regards to thrombocytopenia, one factor that can be overlooked, but may be rapidly reversible, is drug-induced thrombocytopenia. The estimated incidence of drug induced thrombocytopenia varies from 5% to 40% in patients receiving heparin to less than 1% in all other patients. 
Discussion
The most likely cause of thrombocytopenia in our case was determined to be Pantoprazole.
The patient had a normal platelet count on admission with no splenomegaly, ruling out platelet sequestration and underproduction.
The platelet count continued to fall 3 days after the 2 units of Whole Blood were given and the hemoglobin remained stable, which makes dilutional thrombocytopenia unlikely. Similarly, the possibility of infection was also ruled out after clinical examination and lab investigations.
The criteria for assessing Drug induced Thromboctyopenia was given by George et al. 3 ( Table 2 ).
Table 2: Criteria for assessing Drug induced Thrombocytopenia
Criteria Description 1 1) Therapy with the candidate drug preceded thrombocytopenia and 2) recovery from thrombocytopenia was complete and sustained after therapy with the drug was discontinued 2 1) The candidate drug was the only drug used before the onset of thrombocytopenia or 2) other drugs were continued or reintroduced after discontinuation of therapy with the candidate drug with a sustained normal platelet count 3
Other causes for thrombocytopenia were excluded 4
Re-exposure to the candidate drug resulted in recurrent thrombocytopenia Level of evidence I Definite: criteria 1, 2, 3, and 4 met II Probable: criteria 1, 2, and 3 met III Possible: criterion 1 met IV Unlikely: criterion 1 not met Our patient met Criteria 1, 2 and 3. The only change in therapy was pantoprazole, and other causes of thrombocytopenia were ruled out. However, looking at the severity of the disease re-exposure to the candidate drug was not tried. Thus, our patient represents a "probable" case of Pantoprazole induced Thrombocytopenia. Watson et al. 4 described two cases of thrombocytopenia associated with the use of only Pantoprazole 40 mg in comparison to 8 mg/hour in our case. They did an objective causality assessment using the Naranjo probability scale 5 which revealed a probable relationship between thrombocytopenia and Pantoprazole in both of the cases. The Naranjo probability scale 5 is the standard tool used to evaluate drug-induced adverse events.
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The mechanism of this suspected adverse drug reaction is not well understood. The acute changes in the platelet count are not consistent with decreased production via bone marrow suppression; therefore, the mechanism could be via increased destruction of platelets.
Conclusion:
Drug induced thrombocytopenia is a critical complication of use of Pantoprazole. Though rare, the possibility of the same should always be considered, especially in cases of upper gastrointestinal bleed where the risk of bleeding is increased in the presence of thrombocytopenia.
